Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: A 6-month observational study

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Spalletta, Gianfranco ^a   Caltagirone, Carlo ^a,b   Padovani, Alessandro ^c   Sorbi, Sandro ^d   Attar, Mahmood ^e   Colombo, Delia ^e   Cravello, Luca ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e Novartis Farma Italia ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

AFFECT; AGED; ALZHEIMER DISEASE; APATHY; ARTICLE; COGNITION; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHIATRIC INVENTORY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PSYCHOLOGIC ASSESSMENT; TREATMENT OUTCOME;

ALZHEIMER DISEASE; APATHY; CHOLINESTERASE INHIBITORS; DEPRESSION; DRUG SUBSTITUTION; HUMANS; ITALY; MILD COGNITIVE IMPAIRMENT; MOOD DISORDERS; PHENYLCARBAMATES; SOCIOECONOMIC FACTORS;

EID: 84896757411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089216     Document Type: Article

References (37)

1. Di Iulio F, Palmer K, Blundo C, Casini AR, Gianni W, et al. (2010) Occurrence of neuropsychiatric symptoms and psychiatric disorders in mild Alzheimer's disease and mild cognitive impairment subtypes. Int Psychogeriatr 22: 629-640.
2. Bottini G, Berlingeri M, Basilico S, Passoni S, Danelli L, et al. (2012) GOOD or BAD responder? Behavioural and neuroanatomical markers of clinical response to donepezil in dementia. Behav Neurology 25: 61-72.
3. Spalletta G, Musicco M, Padovani A, Rozzini L, Perri R, et al. (2010) Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry 18: 1026-1035.
4. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, et al. (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379-397. (Pubitemid 351665469)
5. Panza F, Solfrizzi V, Frisardi V, Capurso C, D'Introno A, et al. (2009) Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 26: 537-555.
6. Rodda J, Morgan S, Walker Z (2009) Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21: 813-824.
7. Sadowsky CH, Dengiz A, Olin JT, Koumaras B, Meng X, et al. (2009) Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen 24: 267-275.
8. Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B (2002) Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 18: 129-138. (Pubitemid 34665750)
9. Bullock R, Connolly C (2002) Switching cholinesterase inhibitor therapy in Alzheimer's disease-donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 17: 288-289. (Pubitemid 34232602)
10. Dhillon S (2011) Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs 71: 1209-1231.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944. (Pubitemid 14076461)
12. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
13. Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, et al. (2005) Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 21: 1809-1818.
14. Cummings JLMD (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 48: 10S-16S.
15. Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, et al. (2001) National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 9: 346-360. (Pubitemid 33015123)
16. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, et al. (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288: 1475-1483.
17. Steinberg M, Tschanz JT, Corcoran C, Steffens DC, Norton MC, et al. (2004) The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 19: 19-26. (Pubitemid 38180688)
18. Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, et al. (2008) Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm 14: 451-461.
19. Mauskopf JA, Paramore C, Lee WC, Snyder EH (2005) Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 11: 231-251.
20. Gauthier S, Juby A, Morelli L, Rehel B, Schecter R (2006) A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Curr Med Res Opin 22: 2251-2265. (Pubitemid 44789990)
21. Tian H, Abouzaid S, Chen W, Kahler KH, Kim E (2013) Patient Adherence to Transdermal Rivastigmine After Switching From Oral Donepezil: A Retrospective Claims Database Study. Alzheimer Dis Assoc Disord. 27: 182-186.
22. Han HJ, Lee JJ, Park SA, Park HY, Kim JE, et al. (2011) Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol 7: 137-142.
23. Onor ML, Trevisiol M, Aguglia E (2007) Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging 2: 17-32.
24. Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, et al. (2000) Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther 293: 896-902. (Pubitemid 30417856)
25. Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J (2000) Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 15: 242-247. (Pubitemid 30179175)
26. Guillozet AL, Smiley JF, Mash DC, Mesulam MM (1997) Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42: 909-918. (Pubitemid 28008422)
27. Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4: 273-277. (Pubitemid 9001675)
28. Bailey JA, Lahiri DK (2010) A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 112: 843-853.
29. Bailey JA, Ray B, Greig NH, Lahiri DK (2011) Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6(7): e21954.
30. Venneri A, McGeown WJ, Shanks MF (2005) Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 16: 107-110. (Pubitemid 40250379)
31. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, et al. (2006) Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 63: 161-167. (Pubitemid 43213877)
32. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, et al. (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378: 403-411.
33. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, et al. (2010) Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18: 136-145.
34. Spalletta G, Gianni W, Giubilei F, Casini AR, Sancesario G, et al. (2013) Rivastigmine Patch Ameliorates Depression in Mild AD: Preliminary Evidence From a 6-Month Open-label Observational Study. Alzheimer Dis Assoc Disord. 27: 289-291.
35. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL (2006) Neuropathologic correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 21: 144-147. (Pubitemid 43201323)
36. Vicini Chilovi B, Conti M, Zanetti M, Mazzu I, Rozzini L, et al. (2009) Differential impact of apathy and depression in the development of dementia in mild cognitive impairment patients. Dement Geriatr Cogn Disord 27: 390-398.
37. Palmer K, Di Iulio F, Varsi AE, Gianni W, Sancesario G, et al. (2010) Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. J Alzheimers Dis 20: 175-183.